Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282240 | 0.86 | CREBBP (0.40) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL19122771 | 0.82 | CREBBP (0.38) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL13591522 | 0.79 | PTGS2 (0.39) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL13090773 | 0.77 | PTGS2 (0.36) | CREBBPBRD4CA2PTGS2MAOB | |
| SCHEMBL22185345 | 0.76 | CA2 (0.38) | CREBBPBRD4CA2PTGS2CYP1A2 | |
| SCHEMBL10054032 | 0.76 | USP2 (0.37) | CREBBPBRD4CA2PTGS2MAOB | |
| SCHEMBL13817385 | 0.76 | USP2 (0.42) | CREBBPBRD4CA2PTGS2MAOB | |
| SCHEMBL2209905 | 0.74 | AHR (0.50) | CA2CYP1A2MAPTAKR1B1 | |
| SCHEMBL2545956 | 0.74 | AHR (0.50) | CA2CYP1A2MAPTAKR1B1 | |
| SCHEMBL9118213 | 0.74 | CYP1A2 (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022100623-A1 | NITROGEN-SUBSTITUTED HETEROCYCLIC THIOPHENE COMPOUNDS AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-05-19 | — | — | WO | disclosed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160304555-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-9326513-B2 | Fungicidal compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2016-05-03 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7339078-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070037754-A1 | Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide | G.D. SEARLE & CO. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7161033-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161033-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | CREBBP 889/4885BRD4 521/4885CA2 1661/4885 |
| US-20070037754-A1 | Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide | DNPEP, PREP, ANPEP | CREBBP 1164/4885BRD4 442/4885CA2 3017/4885 |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | CREBBP 2549/4885BRD4 1266/4885CA2 2903/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CREBBP 401/4885BRD4 1928/4885CA2 4670/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | CREBBP 942/4885BRD4 3611/4885CA2 3995/4885 |
| US-20160219879-A1 | FUNGICIDAL COMPOSITIONS | CYP1B1, CYP4B1, DDT | CREBBP 4650/4885BRD4 2245/4885CA2 533/4885 |
| US-20160304555-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CREBBP 3111/4885BRD4 2671/4885CA2 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.